{"filings":[{"id":509637,"accession_number":"0001079973-26-000693","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2026-05-19T13:05:52+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifeloc Q1 net loss narrows to $153K; SpinDetect mold milestone achieved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $2.294M (+1% YoY), net loss $153K ($0.06/diluted share) vs $293K loss in Q1 2025.","Gross margin improved to 43% from 40%; R&D spend >18% of revenue.","Completed production mold for SpinDetect drug analyzer; first article disks delivered in April.","Closed $500K loan from Chairman and CFO at 10.5% interest, interest-only in 2026, 5-year term."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":2293812.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93167,"accession_number":"0001079973-26-000624","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Lifeloc Technologies enters $500K promissory note with CFO/Chairman for SpinDetect development","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $500K, 10.5% initial interest, interest-only payments through Dec 31, 2026.","From Jan 2027, 60 equal monthly installments of principal & interest; full balance due Dec 31, 2031.","Note secured by deed of trust on company office and substantially all assets, subordinate to Citywide Banks senior debt.","Proceeds will fund continued development of the SpinDetect product.","Lender is Vern Kornelsen, the company's CFO and Chairman of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104564,"accession_number":"0001079973-26-000377","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifeloc FY 2025 revenue up 6% to $9.027M; net loss widens to $2.47M on deferred tax charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.027M (+6% YoY); net loss $2.470M ($0.90/diluted share) vs $1.053M loss in 2024.","Gross margin stable at 40.3%; pre-tax loss improved to $1.311M from $1.405M.","Deferred tax valuation allowance increased to $1.738M (non-cash) from $187K.","SpinDetect drug analyzer: production mold fabrication started Q1 2026; first articles expected April.","New L-series breath testers (LX9, LT7) certified to AS 3547:2019; driving market penetration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120839,"accession_number":"0001079973-25-001693","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifeloc Technologies Reports Q3 2025 Revenue Up 8% but Net Loss Widens to $263K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net revenue $2.257M, up 8% from $2.087M in Q3 2024, but net loss increased to $(263K) from $(158K).","Gross margin declined to 40.2% from 43.7% due to cost inflation and tariffs.","SpinDetect centrifugal drug analyzer beta testing for THC detection underway; commercial launch expected in 2026.","Nine-month 2025 net loss $(950K) vs $(740K) same period 2024, revenue $6.754M vs $6.628M.","Shares began trading on OTCID July 1, 2025, replacing OTC Pink."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":6753858.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120838,"accession_number":"0001079973-25-001607","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lifeloc Technologies acquires ELST via merger; exchange ratio 0.048","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Each share of ELST common stock will be converted into 0.048 shares of Lifeloc common stock, plus cash for fractional shares.","Lifeloc will form a Merger Sub that will merge into ELST, with ELST surviving as a wholly owned subsidiary of Lifeloc.","Closing conditions include ELST shareholder approval, effectiveness of Lifeloc's S-4 registration statement, and regulatory approvals.","ELST shareholders are entitled to dissenters' rights under Washington law as described in the merger agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137447,"accession_number":"0001079973-25-001492","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lifeloc to present at Emerging Growth Conference on Sep 25; CEO to discuss SpinDetect","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Dr. Wayne Willkomm to present at live virtual Emerging Growth Conference on September 25, 2025 at 2:20 PM ET.","Will provide an update on SpinDetect centrifugal drug analyzer, a microfluidic-based drug screening platform under development.","Webcast registration open; replay to be available on Emerging Growth website and YouTube channel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137446,"accession_number":"0001079973-25-001410","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lifeloc Technologies enters into Amendment No. 3 to License Agreement with Sandia","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["On August 26, 2025, Lifeloc Technologies signed Amendment No. 3 to License Agreement 15-C02736 with National Technology & Engineering Solutions of Sandia, LLC.","The amendment revises provisions on U.S. competitiveness requirements, change of control, assignment, and milestone obligations.","Certain confidential terms were redacted from the exhibit as non-material and proprietary.","The amendment was disclosed in an 8-K filed September 2, 2025 and attached as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137445,"accession_number":"0001079973-25-001238","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifeloc Q2 2025 net loss $(394k), revenue -7% YoY; SpinDx beta testing begins, launch expected early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $2.219M, down 7% YoY; net loss $(394k) ($0.14 loss per share) vs $(298k) loss in Q2 2024.","Gross margin stable at 41.7%; R&D spend $623k primarily on SpinDx drug testing platform.","SpinDx beta testing underway for delta-9-THC detection; commercial launch targeted for early 2026.","Company began trading on OTCID tier of OTC Markets effective July 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":4496410.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154767,"accession_number":"0001079973-25-000997","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Shareholders re-elect five directors and ratify Assure CPA as auditor for FY2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with 2,136,243 votes for and 299 withheld each.","Ratification of Assure CPA as independent auditor passed: 2,249,271 for, 8,600 against.","Annual meeting held June 4, 2025; 2,257,871 of 2,752,616 outstanding shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154766,"accession_number":"0001079973-25-000886","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifeloc Q1 revenue up 6% to $2.28M, net loss $(293k) from $(284k) YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $2.277M (+6% YoY); net loss $(293k) or $(0.11) per diluted share.","Gross margin improved to 39.9% from 38.8%; R&D spending >20% of revenue for SpinDx development.","SpinDx beta testing with Anschutz Medical Center imminent; commercial launch targeted for 2026.","Applied for OTCID listing on OTC Markets, effective July 1, 2025, replacing OTC Pink."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":2277034.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173276,"accession_number":"0001079973-25-000550","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifeloc reports FY2024 net loss of $1.05M on revenue down 8% to $8.54M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.053M ($0.41 diluted EPS) vs net profit of $205.6K ($0.08 EPS) in 2023.","Revenue declined 8% to $8.538M from $9.330M; gross margin fell to 40.4% from 43.3%.","Record R&D investment in SpinDx drug detection; beta testing of THC disk in Q2 2025, commercial launch early 2026.","Closed $750K debenture in Dec 2024 plus $75K in Q1 2025 to fund SpinDx development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":2277034.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173275,"accession_number":"0001079973-25-000046","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Lifeloc Technologies secures $750,000 subordinated debenture with 8.25% interest and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750,000 subordinated debenture to Diamond Bridge Capital at 8.25% interest, maturing Dec 31, 2030; quarterly interest through 2025 then monthly P&I.","Warrant to purchase 62,500 shares at $4.50 per share, exercisable until Dec 31, 2031; includes registration rights.","Proceeds to support growth, fund R&D and commercialization of SpinDx drug detection technology.","Projections show path to profitability by 2027 with sales growing from $8.5M (2024E) to $19.5M (2028E)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190296,"accession_number":"0001079973-24-001502","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifeloc Q3 2024 net loss $158K, revenue down 23% YoY; SpinDx progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $2.087M (down 23% YoY); net loss $158K ($0.06/diluted) vs prior year profit $110K.","Nine-month 2024 revenue $6.628M, net loss $740K ($0.30/diluted) vs prior year profit $111K.","Gross margin improved to 43.7% in Q3 vs 41.5% last year; nine-month 41.4% vs 43.4%.","SpinDx saliva THC detection system beta testing planned this quarter; commercial launch projected later in 2025.","Raised $750K line of credit and $798K private placement (210K shares at $3.80) to fund SpinDx development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":6628099.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206794,"accession_number":"0001079973-24-001179","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifeloc Q2 2024 net loss of $298K; rev $2.387M (+5% YoY); SpinDx beta in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $(298K) ($0.12/diluted) vs net income $55K ($0.02) in Q2 2023.","Revenue increased 5% to $2.387M; gross margin fell to 41.6% from 45.7%.","R&D spending rose 67% to $662K, primarily for SpinDx saliva THC detection.","Cash at $505K; post-quarter closed $750K credit line + $798K private placement.","SpinDx beta testing planned H2 2024; commercial launch targeted for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":4540773.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206793,"accession_number":"0001079973-24-001110","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Lifeloc raises $798K via private placement, appoints new director, secures $750K credit line","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 210,000 shares at $3.80 to EDCO Partners, raising $798K; EDCO now holds 77.5% of common stock.","Robert Greenlee resigned from board; replaced by Adam Kashenberg, CEO of Colorado Biolabs, effective July 23.","Obtained $750K line of credit from Citywide Banks on July 19, 2024.","Plans beta testing of saliva THC test (SpinDx) in 2024, targeting commercial launch in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224048,"accession_number":"0001079973-24-000952","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Lifeloc shareholders re-elect all five directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected with 1,959,965 votes for and 2,329 withheld; no against votes.","Ratification of Assure CPA as independent auditor for FY2024 passed with 1,889,495 votes for, none against.","Total shares outstanding and entitled to vote at the meeting: 2,454,116.","No other proposals were submitted; broker non-votes were zero on all matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224047,"accession_number":"0001553350-24-000056","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Lifeloc Technologies dismisses GreenGrowth CPAs, engages Assure CPA as new auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit committee dismissed GreenGrowth CPAs on May 20, 2024; no disagreements or reportable events occurred.","New auditor Assure CPA, LLC engaged effective May 22, 2024 to audit FY2024 financial statements.","Prior auditor's reports on FY2023 had no adverse opinion or modification; no prior consultations with new auditor.","GreenGrowth CPAs provided a letter to the SEC agreeing with the dismissal disclosures (Exhibit 16.1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224046,"accession_number":"0001079973-24-000738","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifeloc Q1 net loss widens to $284K; revenue flat at $2.15M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $2.153M flat YoY ($2.165M); net loss $(284)K ($0.12/diluted) vs $(54)K loss ($0.02/sh).","Gross margin declined to 38.8% from 43.2% due to inflation-driven cost increases.","R&D spending rose 40% primarily for SpinDx drug testing platform development.","Beta testing of SpinDx saliva THC detection expected later in 2024; commercial launch projected 2025.","Smartphone pairing for LX9 breathalyzer expected in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":2153443.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224045,"accession_number":"0001079973-24-000486","cik":1493137,"company_name":"Lifeloc Technologies, Inc","ticker":"LCTC","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifeloc reports 2023 revenue $9.33M, net profit $206K vs loss prior year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $9.330M (+10% YoY); net profit $206K ($0.08 diluted EPS) vs net loss $456K ($0.19 loss) in 2022.","Gross margin improved to 43.3% from 36.3% due to price increases, lower depreciation, easing supply constraints.","R&D investment increased 32% YoY focused on SpinDx 'Lab on a Disk' drug detection platform.","Beta testing of SpinDx delta-9-THC saliva test expected later 2024; commercialization projected 2025.","CEO says supply constraints no longer significant; L-series devices gaining approvals and market penetration."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":2153443.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6078326.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}